SOAT1 and breast cancer: These analyses indicate that nonresponse to JAK/STAT inhibition could be associated with the tendency to relapse (resistant) in majority of ER-neg, PR-neg breast cancer patients compared to ER-pos/PR-pos patients (Additional file 4: Figure S3B).